Drugs / ELX/TEZ/IVA
Trials 1
| Phase | Registry id | Dates | Indication | Sponsor | Status | Outcome |
|---|---|---|---|---|---|---|
| Phase 3 | NCT04353817 | Jun 2020 → May 2021 | cystic fibrosis | Vertex Pharmaceuticals Incorporated | Completed | Met primary |
News releases announcing trial results or a regulatory action · 4
| Date | Issuer | Release |
|---|---|---|
| 2026-06-05 | Vertex Pharmaceuticals Incorporated | Results Vertex Presents New Data on ALYFTREK® at European Cystic Fibrosis Conference vrtx.com ↗
Long-term 96-week interim analyses from two open-label extension studies demonstrate positive safety and efficacy profile of ALYFTREK in people with cystic fibrosis ages 6 and older |
| 2025-06-06 | Vertex Pharmaceuticals Incorporated | Results Vertex Presents New Data on Benefits of ALYFTREK® and Importance of Achieving Lower Sweat Chloride Levels at the European Cystic Fibrosis Conference vrtx.com ↗ |
| 2024-09-26 | Vertex Pharmaceuticals Incorporated | Results Vertex Highlights First Oral Presentation of Phase 3 Clinical Data of the Vanza Triple and New Data on Long-Term Impact of TRIKAFTA® at the North American Cystic Fibrosis Conference vrtx.com ↗
Vertex also announced presentations describing long-term outcomes in people with cystic fibrosis (CF) ages 2 to 11 years taking TRIKAFTA®, demonstrating consistent and sustained improvements across multiple measures of disease. |
| 2020-09-24 | Vertex Pharmaceuticals Incorporated | Results Vertex to Present New Data at European and North American Virtual Cystic Fibrosis Conferences Highlighting Long-Term Use of CFTR Modulators vrtx.com ↗ |
All press releases naming this drug 4 releases
| Date | Issuer | Release |
|---|---|---|
| 2026-06-05 | Vertex Pharmaceuticals Incorporated | Vertex Presents New Data on ALYFTREK® at European Cystic Fibrosis Conference vrtx.com ↗ |
| 2025-06-06 | Vertex Pharmaceuticals Incorporated | Vertex Presents New Data on Benefits of ALYFTREK® and Importance of Achieving Lower Sweat Chloride Levels at the European Cystic Fibrosis Conference vrtx.com ↗ |
| 2024-09-26 | Vertex Pharmaceuticals Incorporated | Vertex Highlights First Oral Presentation of Phase 3 Clinical Data of the Vanza Triple and New Data on Long-Term Impact of TRIKAFTA® at the North American Cystic Fibrosis Conference vrtx.com ↗ |
| 2020-09-24 | Vertex Pharmaceuticals Incorporated | Vertex to Present New Data at European and North American Virtual Cystic Fibrosis Conferences Highlighting Long-Term Use of CFTR Modulators vrtx.com ↗ |
Evidence & citations 2 cited values
Every value below carries the sentence it was read from. 1 source stands behind the page.
| Field | Value | Cited text |
|---|---|---|
| Known as | ELX/TEZ/IVA | ClinicalTrials.gov intervention name — accepted as the source's own label NCT04353817 ↗ |
| Route | Oral | “Fixed-dose combination tablet for oral administration qd in the morning.” NCT04353817 ↗ |